Leadership

Joël Jean-Mairet, PhD

Board Member

Joël Jean-Mairet is managing partner and co-founder of Ysios Capital. He previously co-founded Glycart Biotechnology and served as its CEO through its sale to F. Hoffmann La-Roche in 2005. Glycart was the originator of an anti-CD20 antibody now named obinituzumab/Gazyva®, the first breakthrough designated drug approved by the FDA for B-CLL. Joël currently serves on the boards of directors of Adcendo, Inbiomotion (Executive Chairman) and AM-Pharma (observer). He has been Chairman of the board of Cellerix/Tigenix (now Takeda), board member of Aura Biosciences (Nasdaq: AURA), SpliceBio and Sanifit Therapeutics (now Vifor Pharma), LAVA Therapeutics (Nasdaq: LAVA), and board observer at Biovex (now Amgen) and Mineralys (observer). Joël has earned numerous awards, including the Wall Street Journal’s Europe Innovation Award in 2001. He holds a PhD from the Swiss Federal Institute of Technology (ETH) in Zurich.